Clinton and Trump agree prescription drugs are too expensive -- and biotech is gearing up for change

This November, the biotech industry faces an awkward decision: Donald Trump, whose policy stances have proven unpredictable; or Hillary Clinton, who can scythe drug company stock prices with a single tweet. But both candidates agree on one thing: Drugs are too expensive. So whatever the outcome, biotech is preparing for more scrutiny on how it makes…